Moteur de recherche d’entreprises européennes
Financement de l’UE (3 995 083 €) : Développement de systèmes d’administration à base de biomatériaux pour la maladie de Parkinson - une approche paneuropéenne intégrée Hor11/08/2015 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Développement de systèmes d’administration à base de biomatériaux pour la maladie de Parkinson - une approche paneuropéenne intégrée
BrainMatTrain focuses on a comprehensive understanding of Parkinson’s disease (PD), from basics to translation, fully supported by 8 full partners partner organisation (4 research institutions, 2 hospitals, 2 SMEs) and one partner organisation (SME specialist in device design). This ETN will educate and train 15 Earlty Stage Researchers (ESRs) in functioanlised biomaterials, materials science, functionlisation strategies, molecular biology, stem cell biology, in vitro model systems, in vivo neuroimaging, animal models and prototype design. Recruited ESRs will receive compulsory discipline-specific, generic and complementary transferable skills training. BrainMatTrain will develop multi-modal collagen reservoir scaffolds incorporating moieties targetitng the neuroinflammatoiry and neuroprotective phases of the underlying pathology of Parkinson’s disease. The researchers will undertake cross-disciplinary and intersectorial research projects, which when married together will deliver a novel, biomaterial-based, therapeutic device for the treatment of Parkinson’s disease. The research training programme is designed to ensure high-calibre graduates, best placed to secure employment in the private or public sector. Fellows will experience both private and public sector research and development environments through a considered secondment plan.
| Collagen Solutions (UK) Ltd. | 546 576 € |
| Commissariat a L Energie Atomique et aux Energies Alternatives | 525 751 € |
| Danmarks Tekniske Universitet | 290 082 € |
| Lunds Universitet | 527 319 € |
| Medizinische Universitat Innsbruck | 255 934 € |
| Orbsen Therapeutics Ltd. | 265 675 € |
| Stichting Radboud Universiteit | 255 374 € |
| University of Galway | 1 328 373 € |
https://cordis.europa.eu/project/id/676408
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
